MediciNova falls 8.9% premarket after fatty liver drug misses significance on blood-fat reduction
The company said MN-001 lowered triglycerides and raised HDL in a mid-stage trial, but the blood-fat reduction was not statistically significant.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.